Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported pain intensity VAS (0‐10, lower score = less pain) · people with moderate to severe cancer pain
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – nausea compared with morphine (very low certainty).
1 finding from 1 review
Vomiting · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – vomiting compared with morphine (very low certainty).
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – dizziness compared with morphine (very low certainty).
1 finding from 1 review
Constipation · people with moderate to severe cancer pain
1 finding from 1 review
Quality of life · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with moderate to severe cancer pain
1 finding from 1 review
Relief of pain · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Vomiting · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Relief of pain · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Constipation · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – nausea compared with oxycodone (very low certainty).
1 finding from 1 review
Vomiting · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – vomiting compared with oxycodone (very low certainty).
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – dizziness compared with oxycodone (very low certainty).
1 finding from 1 review
Constipation · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – constipation compared with oxycodone (very low certainty).
1 finding from 1 review
Quality of life · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review